MorphoSys's licensee Janssen reports positive results from phase 3 DISCOVER 1 & 2 studies of guselkumab in adults with active psoriatic arthritis

Source :: PharmaBiz. June 17, 2019
Publication Year :: 2019
Abstract: MorphoSys AG, announced that its licensee Janssen Research & Development, LLC (Janssen), reported top-line results from the phase 3 DISCOVER 1 and 2 studies. The studies evaluated the efficacy and [...]

Subjects :: MorphoSys AG -- Product development
Guselkumab -- Research -- Product development
Biotechnology industries -- Product development
Psoriatic arthritis -- Research
Biological products industry -- Product development
Adults
Arthritis
Prescription writing
Pharmaceuticals and cosmetics industries
Tremfya (Medication)

Tools